ClinicalTrials.gg
CompletedNCT07229157Updated Sep 22, 2026

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

A Phase 1 interventional study of Maridebart Cafraglutide and Moxifloxacin in Overweight and Obesity, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
23rd of 28
81 · median 275
Started
2025
with 10 others
Phase 1
14 of 28
3 open now
Registered
13th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 23rd largest by enrollment, is one of 11 that started in 2025, is one of 14 in phase 1, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

Keywords

  • Overweight
  • Obesity
  • Maridebart Cafraglutide
  • AMG 133
  • QT/QTc Intervals
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 81 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To take part in the trial, participants must meet all of the following:

  1. Provide signed and dated before any trial procedures.
  2. Be able to understand the trial requirements, sign the consent form, and follow trial restrictions.
  3. Male or female, of any race, between 18 and 60 years old (inclusive).

    • Females must not be pregnant or breastfeeding.
    • Males and females who could become pregnant must agree to use effective as specified in the protocol.
  4. (BMI) between 25.0 and 35.0 kg/m\^2 (inclusive).
  5. No major changes in diet or lifestyle in the past 3 months, based on self-report.
  6. Stable body weight (less than 5 kg change) in the past 3 months, based on self-report.
  7. Blood potassium, calcium, and magnesium within the normal range at screening and at check-in for the first treatment period.
  8. Participants with controlled high blood pressure, cholesterol problems, or hypothyroidism on stable treatment for at least 3 months may be included (except for medicines known to affect heart rhythm or interact with moxifloxacin). Other mild, stable health conditions may be allowed with approval from the investigator and medical monitor.

Exclusion criteria

Exclusion Criteria

Participants will not be able to take part if they meet any of the following:

Medical Conditions

  1. Any significant medical condition or abnormal test result that, in the opinion of the investigator, could pose a risk or interfere with trial participation.
  2. History of diabetes (any type, except past gestational diabetes), or (HbA1c) ≥ 6.5% at screening.
  3. History of pancreatitis within the past year, or high blood tests suggesting pancreatic problems (lipase/amylase > 2× normal, or fasting triglycerides > 500 mg/dL).
  4. Liver enzymes ( [ALT] or aspartate aminotransferase [AST]) more than 2× the .
  5. Kidney function (estimated [eGFR]) \< 70 mL/min/1.73 m\^2.
  6. Cancer within the last 5 years (except treated nonmelanoma skin cancers or in situ cervical/breast lesions).
  7. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
  8. Uncontrolled thyroid disease (abnormal thyroid-stimulating hormone [TSH] outside 0.4-6.0 mIU/L).
  9. to moxifloxacin, including history of tendon disorders with quinolone use.
  10. History of gastrointestinal surgery or disease that may affect absorption of oral drugs (other than uncomplicated appendectomy or hernia repair).
  11. Inability to swallow pills.
  12. History of significant esophageal, stomach, or bowel disorders (eg, ulcers, bleeding, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis).
  13. Current or recent suicidal thoughts (per Columbia Suicide Severity Rating Scale [C-SSRS]).
  14. Lifetime history of suicide attempt or behavior.
  15. Major depressive disorder within the past 2 years.
  16. History of other serious psychiatric disorders (eg, schizophrenia, bipolar disorder).
  17. High depression score (patient health questionnaire-9 [PHQ-9] ≥ 15).
  18. History or current signs of heart disease (eg, heart attack, congenital defects, valve disease, angina, bypass or stent).
  19. History of ischemic optic neuropathy (eye damage from poor blood flow).
  20. Diagnosis of sleep apnea. Diagnostic Tests
  21. Positive test for (HIV).
  22. Positive test for or C (exceptions apply for prior vaccination or resolved infection).
  23. Abnormal vital signs: average blood pressure > 140/90 mmHg or \< 90/50 mmHg, or heart rate > 110 or \< 40 bpm.
  24. Abnormal findings at screening or check-in, including:

    • > 450 ms (males) or > 470 ms (females).
    • QRS > 120 ms, PR > 220 ms, AV block (2nd or 3rd degree).
    • Findings that make QTc measurement unreliable.
    • Risk factors for dangerous arrhythmias (eg, heart failure, low potassium, long QT syndrome).
    • arrhythmias. Medications
  25. Use of drugs that affect absorption, metabolism, or elimination within 30 days of dosing.
  26. Use of drugs known to prolong QT/QTc within 30 days of dosing.
  27. Use of prescription drugs (other than hormone replacement or ) within 14 days of dosing.
  28. Use of long-acting/slow-release medicines still active within 14 days of dosing.
  29. Use of non-prescription products (vitamins, supplements, herbal products) within 7 days of dosing.
  30. Use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/antagonists within 3 months of check-in.

    Other Clinical Trial Experience

  31. Participation in another drug trial within 30 days or 5 drug half-lives (whichever is longer).
  32. Previous exposure to maridebart cafraglutide in this or another trial. Lifestyle
  33. Alcohol use > 21 units/week (men) or > 14 units/week (women).
  34. Alcohol use within 48 hours before check-in.
  35. Positive drug screen or alcohol test at screening or check-in.
  36. History of alcohol or drug abuse within 1 year.
  37. Use of tobacco/nicotine products within 3 months, or positive cotinine test.
  38. Use of caffeine within 48 hours of screening or check-in.
  39. Consumption of grapefruit, Seville orange, or related products within 7 days of check-in.
  40. Consumption of poppy seed-containing foods within 7 days of check-in. Other
  41. Receipt of blood products within 2 months before check-in.
  42. Blood donation within 3 months; plasma donation within 2 weeks; donation within 6 weeks.
  43. Poor veins for blood draws.
  44. Any other reason, in the opinion of the investigator, the participant should not take part.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Group 1

    In treatment period 1, participants will receive placebo for moxifloxacin. In treatment period 2, participants will receive maridebart cafraglutide. In treatment period 3, participants will receive placebo for moxifloxacin.

    Drug: Maridebart Cafraglutide · Drug: Placebo for Moxifloxacin

  • Experimental
    Group 2A

    In treatment period 1, participants will receive moxifloxacin. In treatment period 2, participants will receive placebo for maridebart cafraglutide. In treatment period 3, participants will receive placebo for moxifloxacin.

    Drug: Moxifloxacin · Drug: Placebo for Maridebart Cafraglutide · Drug: Placebo for Moxifloxacin

  • Experimental
    Group 2B

    In treatment period 1, participants will receive placebo for moxifloxacin. In treatment period 2, participants will receive placebo for maridebart cafraglutide. In treatment period 3, participants will receive moxifloxacin.

    Drug: Moxifloxacin · Drug: Placebo for Maridebart Cafraglutide · Drug: Placebo for Moxifloxacin

Interventions

  • Participants will receive maridebart cafraglutide SC.

    Also known as: AMG 133

  • Participants will receive moxifloxacin orally.

  • DrugPlacebo for Maridebart Cafraglutide

    Participants will receive placebo for maridebart cafraglutide SC.

  • DrugPlacebo for Moxifloxacin

    Participants will receive placebo for moxifloxacin orally.

07

What researchers measure

Primary outcomes

  1. Change from Baseline in QTcF for Maridebart Cafraglutide

    Change from baseline in QTcF for maridebart cafraglutide will be the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after maridebart cafraglutide dosing.

    Time frame: Up to Day 171

Secondary outcomes

  1. Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) of Maridebart Cafraglutide

    Time frame: Up to Day 171

  2. Maximum Observed Concentration (Cmax) of Maridebart Cafraglutide

    Time frame: Up to Day 171

  3. Change from Baseline in Heart Rate

    Change from baseline in heart rate will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in HR for the by-time point analysis.

    Time frame: Up to Day 171

  4. Change from Baseline in PR Interval

    Change from baseline in PR Interval will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in PR for the by-time point analysis.

    Time frame: Up to Day 171

  5. Change from Baseline in QRS Duration

    Change from baseline in QRS Duration will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QRS for the by-time point analysis.

    Time frame: Up to Day 171

  6. Categorical Outliers for QTcF

    Time frame: Up to Day 171

  7. Categorical Outliers for HR

    Time frame: Up to Day 171

  8. Categorical Outliers for PR

    Time frame: Up to Day 171

  9. Categorical Outliers for QRS

    Time frame: Up to Day 171

  10. Number of Participants with Treatment-emergent Changes in Electrocardiogram (ECG) Morphology

    Time frame: Up to Day 171

  11. Change from Baseline in QTcF for Moxifloxacin

    Change from baseline in QTcF for moxifloxacin will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after moxifloxacin dosing for both the assay sensitivity and by-time point analysis.

    Time frame: Up to Day 171

  12. Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events

    Time frame: Up to Day 232

  13. Number of Participants with Anti-maridebart Cafraglutide Antibody Formation

    Time frame: Up to Day 232

08

Study locations

2 sites
  • Fortrea Clinical Research Unit - Daytona Beach
    Daytona Beach, Florida 32117-5116, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247-4968, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Aug 2026, 10 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 14, 2025
StartActual
Oct 22, 2025
Primary completionActual
Aug 27, 2026
CompletionActual
Aug 27, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07229157
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Oct 22, 2025
Primary completion
Aug 27, 2026
Completion
Aug 27, 2026
Last update
Sep 22, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Maridebart cafraglutide · Moxifloxacin

Start the discussion